tiprankstipranks
Trending News
More News >
Dr. Lal PathLabs Limited (IN:LALPATHLAB)
:LALPATHLAB
India Market
Advertisement

Dr. Lal PathLabs Limited (LALPATHLAB) AI Stock Analysis

Compare
0 Followers

Top Page

IN:LALPATHLAB

Dr. Lal PathLabs Limited

(LALPATHLAB)

Rating:70Outperform
Price Target:
₹3,493.00
▲(5.46% Upside)
Dr. Lal PathLabs scores a 70, driven by strong financial performance and bullish technical indicators. However, the high valuation reflects potential overpricing, and the absence of significant earnings call insights or corporate events limits further analysis. Investors should weigh the robust financial health and growth potential against the current market valuation.

Dr. Lal PathLabs Limited (LALPATHLAB) vs. iShares MSCI India ETF (INDA)

Dr. Lal PathLabs Limited Business Overview & Revenue Model

Company DescriptionDr. Lal PathLabs Limited (LALPATHLAB) is a leading diagnostic and healthcare service provider in India, renowned for offering a wide range of diagnostic and related healthcare services. Established with a focus on quality and reliability, the company operates a network of laboratories, patient service centers, and pick-up points across the country. Its core services include routine and specialized testing services in areas such as biochemistry, hematology, clinical pathology, microbiology, and molecular diagnostics, catering to the needs of patients, physicians, and hospitals.
How the Company Makes MoneyDr. Lal PathLabs Limited generates revenue primarily through the provision of diagnostic and testing services. The company's revenue model is centered around conducting a variety of tests, ranging from routine blood tests to complex genetic and molecular diagnostics. Key revenue streams include fees charged for tests and diagnostics conducted at their laboratories and service centers. The company also collaborates with hospitals and clinics to offer specialized pathology services. Additional revenue is derived from home collection services, where samples are collected from patients' homes, providing convenience and accessibility. Dr. Lal PathLabs has also engaged in strategic partnerships and alliances to enhance its service offerings and expand its reach, contributing to its revenue growth.

Dr. Lal PathLabs Limited Financial Statement Overview

Summary
Dr. Lal PathLabs exhibits a robust financial position characterized by significant revenue and profit growth, efficient operational margins, and a stable balance sheet. Strong cash-generating capabilities further enhance its financial health, positioning the company for future growth despite some areas for improvement in return metrics.
Income Statement
85
Very Positive
Dr. Lal PathLabs showed strong financial performance with a consistent increase in total revenue over the years, marking a significant growth rate from 2024 to 2025. The company enjoys robust profit margins with a gross profit margin of approximately 60.8% and a net profit margin of about 19.8% in the latest year. Both EBIT and EBITDA margins indicate healthy operational efficiency, demonstrating the company's ability to convert revenue into profits effectively.
Balance Sheet
75
Positive
The company maintains a solid financial structure with a low debt-to-equity ratio, indicating conservative leverage. The equity ratio is strong, suggesting a high level of equity financing relative to assets. However, the return on equity shows room for improvement, reflecting moderate efficiency in generating returns for shareholders. The overall balance sheet displays stability and low-risk financial management.
Cash Flow
80
Positive
The cash flow statement reveals a positive trajectory in operating cash flow, aligning well with net income and showcasing strong cash-generating capabilities. Free cash flow has grown significantly, highlighting efficient capital expenditure management and prudent cash utilization. Despite some fluctuations in investing and financing cash flows, the company demonstrates an ability to maintain liquidity and support its growth strategies.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue24.61B24.61B22.27B20.17B20.87B15.81B
Gross Profit12.90B14.97B12.79B15.70B13.00B11.84B
EBITDA7.62B6.96B6.78B5.32B6.13B4.88B
Net Income4.87B4.87B3.58B2.39B3.45B2.92B
Balance Sheet
Total Assets27.17B27.17B24.56B23.86B23.53B16.61B
Cash, Cash Equivalents and Short-Term Investments11.65B11.65B9.43B8.51B6.82B9.84B
Total Debt1.57B1.57B2.47B4.20B5.32B1.50B
Total Liabilities5.10B5.10B5.71B6.86B8.10B3.85B
Stockholders Equity21.73B21.73B18.49B16.66B15.08B12.45B
Cash Flow
Free Cash Flow0.005.25B4.78B4.11B-294.49M3.39B
Operating Cash Flow0.005.69B5.35B4.56B4.47B3.98B
Investing Cash Flow0.00-3.03B-242.69M-2.87B-4.49B-2.12B
Financing Cash Flow0.00-3.34B-4.14B-2.83B1.36B-1.39B

Dr. Lal PathLabs Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3312.00
Price Trends
50DMA
3054.51
Positive
100DMA
2923.48
Positive
200DMA
2853.68
Positive
Market Momentum
MACD
84.29
Positive
RSI
58.78
Neutral
STOCH
28.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LALPATHLAB, the sentiment is Positive. The current price of 3312 is above the 20-day moving average (MA) of 3281.76, above the 50-day MA of 3054.51, and above the 200-day MA of 2853.68, indicating a bullish trend. The MACD of 84.29 indicates Positive momentum. The RSI at 58.78 is Neutral, neither overbought nor oversold. The STOCH value of 28.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LALPATHLAB.

Dr. Lal PathLabs Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
₹277.46B53.79
0.73%10.57%34.11%
51
Neutral
$7.86B-0.26-41.41%2.22%22.87%-2.01%
₹92.45B47.97
0.14%
69
Neutral
₹67.03B62.98
1.66%21.82%36.97%
65
Neutral
₹103.46B68.87
0.20%22.34%20.71%
64
Neutral
₹113.57B74.25
0.71%12.86%10.42%
62
Neutral
₹25.49B31.65
0.32%13.78%32.19%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:LALPATHLAB
Dr. Lal PathLabs Limited
3,312.00
-45.56
-1.36%
IN:JLHL
Jupiter Life Line Hospitals Ltd.
1,410.10
55.71
4.11%
IN:KRSNAA
Krsnaa Diagnostics Limited
785.90
80.66
11.44%
IN:METROPOLIS
Metropolis Healthcare Ltd.
2,192.25
77.95
3.69%
IN:THYROCARE
Thyrocare Technologies Ltd
1,264.85
438.47
53.06%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,007.20
111.71
12.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 02, 2025